Carlos Arteaga

Arteaga is recognized as an expert in the field of breast cancer research. He has demonstrated the utility of targeting TGF-β, which causes cancer to spread, metastasize, and become resistant to chemotherapeutic drugs. He was involved in the development of trastuzumab in combination with chemotherapy for patients with HER2-mutated cancer. Among his current research areas is triple-negative breast cancer, for which there are no targeted therapy options. He is a principal investigator for the Stand Up To Cancer (SU2C) "Targeting the PI3K Pathway in Women's Cancers" Dream Team, which provides $15 million is research funding for a research team spread across 7 institutions. == Awards ==

• 2015 Prize for Scientific Excellence in Medicine, American-Italian Cancer Foundation • 2014 President, American Association for Cancer Research • 2014 Grant W. Liddle Award, Vanderbilt University • 2013 Elected Fellow, American Association for the Advancement of Science • 2011 Brinker Award for Scientific Distinction in Basic Science, Susan G. Komen Foundation • 2009 Gianni Bonadonna Award, American Society of Clinical Oncology • 2005 Elected Member, Association of American Physicians • 2004–2007 Board of Directors, AACR • 2003 AACR-Richard & Hinda Rosenthal Award • 1998 Elected Member, American Society for Clinical Investigation • 1995–2000 Clinical Investigator Award, U.S. Department of Veteran Affairs == References ==